Sie sind auf Seite 1von 5

Compilation abstracts which have been approved to be presented at

1) CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD) AND EMPHYSEMA

Control/Tracking Number: 2009-O-419-ISSCR


Activity: Oral
Current Date/Time: 2/22/2009 1:44:03 PM

IMPROVEMENT OF COPD AND EMPHYSEMA WITH AMINISTRATION OF


UNFRACTIONS AUTOLOGOUS BONE MARROW ( WORLD PIONEER EXPERIENCE
FROM ARGENTINA)

Author Block Fernandez Vina, Roberto1, Saslvsky, Jorge2, Andrin, Oberdan3,


Vrsalovic, Francisco1, Fernandez Vina, Federico1, Camozzi, Liliana3, Ferreira da Silva
Lima, Janaina4
1
Stem cels therapy and Interventional Cardiology, Fernandez Vina Foundation Argentina
and Maimonides University Buenos Aires Argentina, Buenos Aires, Argentina, 2Stem cels
therapy and Interventional Cardiology, Medicine School University of Rosario Argentina,
Rosario, Argentina, 3Stem cels therapy and Interventional Cardiology, Fernandez Vina
Foundation Argentina & San Nicolas Private Hospital, Buenos Aires, Argentina, 4Stem
cels therapy and Interventional Cardiology, Fernandez Vina Foundation Argentina,
Buenos Aires, Argentina

Abstract:

Objetives: To present the firsts reports and follows up from Argentina of 33 patients,
who carry severe chronic obstructive pulmonary disease Emphysematous kind treated
with Unfractions Autologous Bone Marrow , All patients have a smoking history for
30-40 years, quit smoking since 6 years ago. Using oxygen 2 lpm 24/7, Ipratropium,
nebulizaded Salbuterol , prednison. Grade III-IV short of breath.

Material and Methods: Laboratory Data: Forced vital capacity: 0.5 l (12%), VEF1:
0,30 l (10%) y 0,42 l (13%) post-bronchiodilator, FEF 25-75: 0,14 l/sec(8%), MVV: 11
l/min(10%); TLC: 2.90 l/min (46%), Diffusion Capacity: 10.2 ml/mmHg/min (64%).The
patients were submitted to a procedure to extract 600 ml of bone marrow, that
presented: Total cells 9184 x10p6/ ml, Total mononuclears 3218 x10p6/ml, CD34+: 4,8
x10p6/ml, CD34+CD38-: 0,72 x10p6/ml. Using IV infusion, in a rhythm of infusion of
300 ml/h .

Evolution and Results: After 60 days of the procedure all the patients were
submitted to clinical and laboratorial controls, which presented: Saturation 95-97% in
room air, while exercising, free of oxygen. Dispnea Grade 2, decreased of the required
medication to 1 Salbuterol nebulization per day in all cases and 12 of them with 1
doses of Ipratropio per day, All patients decreased the doses of prednisone and finally
quit with this medication totally. Laboratory data: Forced Vital Capacity: 1,94 l , VEF1:
0,69 l y 0,88 l, FEV25-79: 0,38 l/sec, MVV: 58 l/min, TLC is normal, Diffusion Capacity is
Normal.

Conclusions: The autologous adult stem cell from Unfractions Autologous Bone
Marrow implanted in lung improve the pulmonary function in patients at less in lung
terminal diseases.

2) HEARTH CONDITIONS – CHRONIC MYOCARDIAL ISCHEMIA AND MYOCARDIAL


INFARCTION

Control/Tracking Number: 2009-O-417-ISSCR


Activity: Oral
Current Date/Time: 2/22/2009 1:43:21 PM

ADMINISTRATION OF UNFRACTIONS AUTOLOGOUS BONE MARROW IN


CHRONIC CORONARY DISEASE ( ARGENTINA PIONEER EXPERIENCE)

Author Block Fernandez Vina, Roberto J.1, Saslavsky, Jorge2, Andrin, Oberdan3,
Vrsalovic, Francisco3, Fernandez Vina, Federico4, Camozzi, Liliana5, Ferreira da Silva
Lima, Janaina4, Murad Neto, Stans6, Tuma, Jorge7
1
Stem cels therapy and Interventional Cardiology, Fernandez Vina Foundation Argentina
and Maimonides University Buenos Aires Argentina, Buenos Aires, Argentina,
2
Hematology, Medicine School University of Rosario Argentina, Rosario, Argentina,
3
Stem cels therapy and Interventional Cardiology, Fernandez Vina Foundation Argentina
& San icolas Private Hospital, Buenos Aires, Argentina, 4Stem cels therapy and
Interventional Cardiology, Fernandez Vina Foundation Argentina & San Nicolas Private
Hospital, Buenos Aires, Argentina, 5Laboratory Clinic, Fernandez Vina Foundation
Argentina, Buenos Aires, Argentina, 6Stem cels therapy and Interventional Cardiology,
Instituto de Cardilogia de Post Grado Rio De Janeiro Brasil, Rio de Janeiro, Brazil, 7Stem
cels therapy and Interventional Cardiology, La Maison de Sante & San Felipe Clinic
Lima, Lima, Peru

Abstract:

Objetives: Unfractions Autologous Bone Marrow may be used in the treatment of


chronic myocardial ischemia and myocardial infarction.

Method: 70 patients with refractory angina or cardiac failure and no possibility of


surgical revascularization were included. The age of patients (46 men and 24 women)
oscillated between 53 and 71 years old. Electrocardiograms showed MI Sequel in
different walls of the both ventricles. Echocardiograms showed extensive
Myocardiopathy with Diastoles diameter oscillating form 65 to 73mm and the FEjection
oscillating between 32% and 34%. Stress test revealed in 52 patients anterior wall and
apical necrosis with severe perinecrótic ischemia; in 29 patients inferior and lateral
necrosis; and 63 multiple ischemic areas, Ventriculography revealed increment of
EDVolume and ESystole Volume, with FE oscillating between 32% and 36%. The Cell
Implant was made by “Retrograde Injection through the Sinus Coronary Vein totally
occluded with balloon”. The volume injected was 150cc The average of total
mononuclears cells implanted 9 x 10p8.

Follow up: After a period of three month a progressive increase of sectors contractility
was observed in the echocardiograms. After 180 days it was observed that FE had
improved between 38% and 51%. Scintigraphy controls revealed improvement of the
perfusion in 62 patients of the perinecrótic and diffuse ischemic areas, 65 patients were
subject to Ventriculography, after 360 days and it was observed that the FE improved
up to 48%.

Conclusions: The injection of Unfractions Autologous Bone Marrow has demonstrated


improvement of the perfusion, surely through angiogenesis that produced the FE
increase, objectived by echocardiograms, and Ventriculography. 92% of the patients,
showed an improvement of the contractility of border zone of scars. It was not
observed any progression of coronary occlusive disease after a period of 4 year.
45patients have achieved 2 year of evolution and they are asymptomatic or in
functional class I-II.

3) DIABETES TYPE 1

Control/Tracking Number: 2009-O-416-ISSCR


Activity: Oral
Current Date/Time: 2/22/2009 1:42:00 PM

REPORT FROM ARGENTINA OF FIRST THREE YEARS FOLLOWS UP OF


AUTOLOGOUS STEM CELLS IMPLANT IN DIABETES TYPE 1 (WORLD WIDE
PIONEER EXPERIENCE )

Author Block Fernandez Vina, Roberto


Fernandez Vina Foundation Argentina, Buenos Aires, Argentina

Abstract:

Background: The adult stem cells CD34 (+)CD38(-) have the capacity to differentiate
in functional cells on endocrine pancreas We did the first implant of ASC in the world in
diabetes 1 in 2005 .

Objectives: To report the long time performance of Diabetic type 1 patients treated
with Stems cells implant.

Method: Following the first three years on cell therapy for diabetes 1, the conclusions
are optimistic. In this study we have observed the evolution of 38 Diabetic type 1
patients, 20 male, 18 female, average age 23.06 years old (±20.2). All the patients
were under insulin therapy. For the transplantation we harvested bone marrow from
iliac crest by aspiration, then the sample was processed using a density gradient
separation method, obtained 120ml (±95) of CD34(+) and CD38(-) cells solution. For
the implant we made a procedure of catheterization through Spleen Artery. No
complications or further events were observed during or after the procedure. The
patients were sent to clinical and blood samples control during the 12 months following
the implant.

Results:
C-Peptide Basal (ng/ml), Basal 0.39 --- 6 Months 0.54 --- 36 Months 1.95 --- Increment
98.30%,
C-Peptide after meal (ng/ml), Basal 0.46 --- 6 Months 0.56 --- 36 Months 2.54 ---
increment 151.63%,

H1c Basal 8.4 --- 6 Months 7.39 --- 36 Months 6,54 --- Decrement 24.58%,

Insulin Basal (MU/ml), Basal 5.09 --- 6 Months 12,25 --- 36 Months 18.66 ---
Increment23,25%,

Insulin Doses (IU/day): Basal, 54,96 --- 6 Months 35.8 --- 36 Months 12.60 ---
Decrement 65,44%

Conclusions: the implant of mononuclear CD34+ CD38- ( stem cells) from autologous
bone marrow improves pancreatic function in patients with type 1 diabetes, in a safe
form and is maintained after 3 years at least

4) DIABETES TYPE 2

Control/Tracking Number: 2009-P-436-ISSCR


Activity: Poster
Current Date/Time: 2/22/2009 1:41:12 PM

FIRST REPORT FROM ARGENTINA OF FIRST THREE YEARS FOLLOWS UP OF


AUTOLOGOUS STEM CELLS IMPLANT IN DIABETES TYPE 2

Author Block Fernandez Vina, Roberto1, Ferreira da Silva Lima, Janaina2, Saslavsky,
Jorge3, Andrin, Oberdan1, Vrsalovic, Francisco4, Fernandez Vina, Federico1, Camozzi,
Liliana5, Dadamo, Carla6
1
Stem Cells Therapy and Interventional Cardiology, Fernandez Vina Foundation
Argentina and Maimonides University Buenos Aires Argentina, 3Hemetology, Medicine
School University of Rosario Argentina, Rosario, Argentina, San Nicolas Private Hospital,
Buenos Aires, Argentina, 5Laboratory of Cells Therapy, Fernandez Vina Foundation
Argentina & San Nicolas Private Hospital, Buenos Aires, Argentina, 6Stem Cells Therapy
and Interventional Cardiology, San Nicolas Clinic & Hospital, Buenos Aires, Argentina

Abstract:

Objectives: To evaluate the long time performance of Stem cells implant in pancreas
in Diabetes Tipe 2 patients The adults stem cells CD34(+)CD38(-) have demonstrate
the capacity to differentiate in functional cells on endocrine pancreas.

Method: After three year on cell therapy for diabetes patients the conclusions are
optimistic. In this study we observed the evolution of 58 patients Diabetic type 2, 37
male, 21 female, 29- 71 years old. 29 patients were under insulin therapy, and 20
patients using Sulphonilureas + Biguanidas. For the transplant were harvest bone
marrow from iliac bone crest by aspiration, thereafter the sample was processed using
a density gradient separation method, obtained 120ml (±95) of CD34(+)CD38(-)
solution. For the implant we did a procedure of catheterization through Spleen Artery.
No complications or further events were observed during or after the procedure. The
patients were subject to clinical and blood samples control during the following 36
months following after implant
Results:
C Peptide (ng/ml), Before Implant 1.18 --- 6 Months 1.17 --- 36 Months 2.19 ---,
Increment 48.42%, C-Peptide after meal (ng/ml), Before implant 2.22 --- 6 months 2.95
--- 36 months 4.40 --- Increment: 95.52% (p=0.0036) HBC1: 9.14 basal --- 8.25 at 6
months --- at 36 months 6.35 --- Decrement 21,25% (P=0.003) Insulin Basal (MU/ml
12.33 --- 6 months 15.27 --- 36 months 15.02
--- Increment 25.26% Insulin After Meal (MU/ml) 19.11 --- 6 months 15.27 --- 36
months 34.7 --- Increment: 58,75% (P=0.016)
Pills per day 2,25 prior implant --- after 36 months 0.33 --- (decrement of use 44.36%
( P= 0.0007) Insulin dose (IU/day) basal 50.59 --- after 36 months 9.55 --- Decrement
89,03% (p=0.037)

Conclusions: the implant of mononuclear CD34+CD38- ( stem cells) from autologous


bone marrow improve pancreatic function in patients with type 2 diabetes, in a safe
form and is maintained after 3 years at least